Log in with your email address username.


[Correspondence] Reporting of immune checkpoint inhibitor-associated myocarditis

We read with interest the Correspondence by Javid J Moslehi and colleagues,1 who used the WHO Vigibase reporting system, to describe the first case series of severe myocarditis after treatment with immune checkpoint inhibitors—an emerging clinical entity.2 They noted that fatality was increased with combination therapy and saw substantial increases in reporting over time (especially in 2017).